Brean Capital Initiates Coverage on Zeltiq Aesthetics Inc(NASDAQ:ZLTQ). The shares have been rated Buy. The rating by Brean Capital was issued on Apr 13, 2016.
In a different note, On Feb 16, 2016, Leerink Swann said it Maintains its rating on Zeltiq Aesthetics Inc. In the research note, the firm Lowers the price-target to $44.00 per share. The shares have been rated ‘Outperform’ by the firm. On Jan 22, 2016, Griffen Securities said it Upgrades its rating on Zeltiq Aesthetics Inc. The shares have been rated ‘Buy’ by the firm.
Zeltiq Aesthetics Inc (ZLTQ) shares turned negative on Fridays trading session with the shares closing down -0.07 points or -0.23% at a volume of 3,28,675. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $29.98. The peak price level was also seen at $29.98 while the days lowest was $29.28. Finally the shares closed at $29.73. The 52-week high of the shares is $38.49 while the 52-week low is $18.41. According to the latest information available, the market cap of the company is $1,169 M.
Zeltiq Aesthetics Inc(ZLTQ) last announced its earnings results on Feb 29, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $78.22M. Analysts had an estimated revenue of $77.17M. Earnings per share were $0.05. Analysts had estimated an EPS of $0.11.
Several Insider Transactions has been reported to the SEC. On Mar 23, 2016, Mark J Foley (President and CEO) sold 9,698 shares at $25.01 per share price.Also, On Dec 9, 2015, Andrew N Schiff (director) sold 32,782 shares at $30.09 per share price.On Dec 8, 2015, Mary Fisher (director) sold 30,000 shares at $30.09 per share price, according to the Form-4 filing with the securities and exchange commission.
ZELTIQ Aesthetics Inc. is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product the CoolSculpting System is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system to dermatologists plastic surgeons and aesthetic specialists and generates revenue from sales of its CoolSculpting system and from sales of consumables to its customers. Consumables are the CoolSculpting procedure packs that it sells which are needed to perform procedures using its CoolSculpting system. As of December 31 2014 it had an installed base of 3176 CoolSculpting systems installed across approximately 2688 practices across the world. As of December 31 2014 1.5 million CoolSculpting cycles had been shipped to its customers and distributors.